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1. Introduction 
Seidlin, Oshry and Yallow first examined the feasibility of using radioactive iodine, 131I, to 
treat thyroid carcinoma in 1948. Medical professionals have since adopted 131I extensively to 
treat both benign and malignant thyroid diseases (Rosario et al., 2004; Chen et al., 2003; Berg 
et al., 1996). 131I is commonly used in ablative or adjuvant therapy after thyroid carcinoma 
treatment, which often requires total or near-total thyroidectomy (Chen et al., 2003). Large 
doses of 131I are routinely administered to patients to treat thyroid remnants at Chung-Shan 
Medical University Hospital (CSMUH); however, research on the effective half-life (Teff) in 
the whole-body, thyroid and other organs in vivo has been lacking (CSMUH, 2005). 
Therefore, this study seeks to yield clear scintigraphic images using -camera. 
1.1 Teff by International Commission on Radiological Protection 30 (ICRP 30)  
It is important to evaluate the Teff of the whole-body and each organ in order to calculate the 
internal medical dosimetries in patients. Many studies have reported and recommended 
both the short-term 12-day biological half-life (Tbio) and the long-term 120-day Tbio of 131I 
(ICRP 30, 1978). Nonetheless, not all of the values necessarily apply directly to patients 
without normal functioning thyroids or who have partially removed thyroid glands; the Teff 
of 131I in patients who have undergone total or near-total thyroidectomy differs significantly 
from that of normal people (ICRP 30, 1978). 
Because the body compartments that store iodine in patients who have undergone total or 
near-total thyroidectomy are smaller, the Teff of 131I is shorter considering both physical 
decay and biological elimination (North et al., 2001). The Teff of 131I in various organs, 
including residual normal and neoplastic thyroid tissues, breast, liver, salivary glands and 
stomach, needs to be evaluated in order to calculate the internal medical doses and graph 
the time-activity curves (TAC). Prior studies have used NaI(Tl), an ion chamber and 
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calculation models to evaluate the iodine uptake in the neck using whole-body scans (WBSs) 
(North et al., 2001; Samuel and Rajashekharrao, 1994; Snyder et al., 1983). However, the 
activities of the whole-body, thyroid remnant and other organs have not been analyzed to 
re-evaluate the biodistributions, Teff or internal medical doses in Taiwanese patients. 
1.2 Nuclear properties of radioiodine 
131
I 
While the knowledge of radiation dosimetry in most organs are not yet thorough, the 
investigation of the radiation dosimetry in the thyroid using radioiodine, particularly the 131I 
isotope, has been extensive. North et al. (2001) have derived the age-dependent absorbed 
doses in the thyroid. 131I is generated by neutron irradiation of tellurium dioxide in a nuclear 
reactor. 131I then decays to form stable 131Xe with a half-life of 8.04 days, during which it emits 
606 keV (maximum) and 191 keV (mean) ǃ-particles as well as 364.5 keV and 637 keV Ǆ-rays of 
81.7% abundance (Shieley & Lederer, 1978). The ǃ-particles (ǃ3) are maximal in abundance at 
63.9 keV and 89.9% per transition. The fraction of ǃ-particles absorbed is assumed to be 1, but 
it varies according to the energy of photon; the actual maximum energy absorbed is 172 keV 
Bq-1 s-1. 131I is administered post-operation: 1) to minimize recurrence because the ǃ-particles 
may destroy microscopic carcinoma; 2) because the 364.5 keV Ǆ-rays allow post-ablative 131I to 
detect occult metastases; 3) to ablate residual normal thyroid tissue.  
2. Materials and method 
Five female patients of 41±4.4 years of age who weighed at 54.6±5.4 kg were diagnosed with 
papillary thyroid cancer during routine physical examinations from 2002 to 2004 in central 
Taiwan. All patients had differentiated carcinoma of the thyroid treated by total 
thyroidectomy followed by 1100 MBq 131I therapy administered by the Department of 
Nuclear Medicine at Chung-Shan Medical University Hospital (CSMUH). Table 1 displays 
the characteristics of the five patients where no evidence of neck lymph node or distant 
metastases was present. The patients were treated with 131I and WBSs were conducted using 
a Ǆ-camera at 6 weeks post-operation. Written informed consent for further whole-body 
studies was obtained from all patients. Medical professionals conducted this study with the 
approval from CSMUH Institutional Review Board (IRB).  
 
Case 
no 
Gender age 
Weight 
(kg) 
Syndrome status of remnant 
1 Female 37 55 papillary thyroid cancer Complete ablation 
2 Female 37 58 papillary thyroid cancer minimal residual 
3 Female 38 41 papillary thyroid cancer minimal residual 
4 Female 46 57 papillary thyroid cancer Complete ablation 
5 Female 47 62 papillary thyroid cancer complete ablation 
Table 1. The characteristics of the five patients who underwent whole-body scans (WBSs) at 
Chung-Shan Medical University Hospital (CSMUH). 
2.1 
131
I capsules 
Syncor International Corporation manufactured and delivered carrier-free 131I-NaI capsules 
in a single batch. Medical professionals administered 131I capsules to the patients. Each dose 
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exceeded 99.9% radionuclide purity and 95% radiochemical purity. Verified by spot checks, 
the coefficient of variance (%CV) between capsules in a single batch did not exceed 1.0% 
(CSMUH, 2005). Furthermore, the 131I-NaI capsules were ingested orally at CSMUH to 
minimize the radioactivity released into the environment during handling, compared to the 
high specific activity if sodium iodine were administered in liquid solutions. 
2.2 Image acquisitions 
Nuclear medicine physicians treated patients who had undergone thyroidectomy with 100 
MBq (29.5 mCi) 131I six weeks after surgery when thyroid medications were discontinued. 
The patients then return for in vivo WBSs in a week. No drugs containing iodine or 
radiographic contrast agents were administered to the patients prior to the WBSs. The 
patients were given a light breakfast and asked to urinate on day 1 before the WBSs. At the 
end of day 1, the patients were discharged after the health physicist had verified that the 
patient’s whole-body retention of 131I is within the regulatory limit set by the governing 
body (CSMUH, 2005; Rosario et al., 2004; United States Nuclear Regulatory Commission, 
1997), which allows the patients to have an external dose rate of under 50 μSv (5 mrem) per 
hour at a distance of 1 meter. The number of pixels was maintained constant over all 
subsequent images and the same regions of interest (ROIs) were captured in all scans. 
2.3 In vivo WBS via E-CAM γ-camera  
Medical Physicists drew ROIs to quantify the 131I radioactivity uptake in various organs. In 
vivo WBSs were performed using a Canberra 7350-PE collimator connected to a 19-inch high 
× 13-inch wide × 5/8-inch thick NaI(Tl) crystal Siemens E-CAM Ǆ-camera positioned at a 
fixed distance of 5 centimeters from the patient’s body (Siemens, 1998). Figure 1 displays the 
scintigraphic images from the 20-minute WBSs of patient case no 4. An experienced nuclear 
medicine professional analyzed the images and selected the thigh to subtract the 
background (Chen et al., 2003). Quality assurance, regular quality controls and energy peak 
calibration of the NaI(Tl) detector were performed and energy resolution test results were 
calibrated daily by the CSMUH staff (CSMUH, 2005; Siemens, 1998). To ensure the drop in 
uptake by the lesion following therapeutic dose administration was not related to increased 
Ǆ-dead-time, the linearity of the E-CAM counting rate was calibrated for the radioactivity 
range encountered. Medical physicists determined the Teff of each organ by linearly 
regressing and then dividing the natural logarithm of the dose injected (%ID) into the 
whole-body at hour 24. Figure 2 displays the time-activity curves (TACs) of representative 
ROIs from the bladder, the brain, kidneys, the liver, lower large intestine (LLI), the thigh, the 
thyroid remnant and the whole-body of a 46 year-old female patient. The area under the 
corresponding fitted curve is also calculated.  
2.4 Effective and biological half-life (Teff and Tbio)  
Medical professionals used Ǆ-camera to collect the activity of each organ in vivo and 
generated the TACs for dosimetric calculations. The sum of the organ counts was subtracted 
from the whole-body counts. Both biological elimination and physical decay account for the 
131I activity decay in thyroidectomy patients. Teff is evaluated using the formula, 
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1
T
 + 
phy
1
T
  (1) 
where Tphy is the physical half-life (Tphy) of 131I which is 8.04 days (Pacilio et al., 2005; Shieley 
and Lederer, 1978).  
The activity (Ai) is measured at different times (Ti) to re-estimate the Teff, 
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T
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Fig. 1. The anterior whole-body scans of a 46-year-old female patient (case no 4) in (a) 3 
hours (b) 46 hours and (c) 142 hours after 131I administration.  
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Fig. 2. The time-activity curves (TACs) for the whole-body and each organ calculated from 
direct measurements of the 46-year-old female patient in organ-specific ROIs without decay 
correction. ■represents the whole-body; ː, LLI; ○, the bladder; ◆, the liver; ˏ, the brain; 
▽, the kidneys. The area under the curve is obtained using the trapezoidal rule from the 
origin to the last activity measured and the Teff is used to evaluate the remaining area under 
the TAC to infinity for dosimetric calculations. 
2.5 Data analysis  
The radioiodine ingested by the patients is completely absorbed by the stomach into blood 
and does not pass through other compartments of the gastrointestinal tract (ICRP 26, 1990). 
The first scan was performed 2 hours after treatment, and therefore the regressed data were 
normalized to 100% on day 2. A0 is the activity of each organ on day 2. Ai is the cumulative 
activity (sum of all nuclear transitions) in source organ letter i (μCi h or MBq s), and it can be 
determined by various in vivo scanned pixels under the assumed conditions. Computer 
counts for each ROI were converted into activity. The weighted mean (Aw) of Ai is (Pan and 
Chen, 2001; Stabin et al., 1999; Saha, 1997), 
 Aw = 
i i
i
W A
W

  (3) 
where the weighting factor (Wi) is obtained from the percentage standard deviation (%σi) 
and the standard error (σi):  
 σi = iA  (4) 
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 σi %=(100 iA )%  (5) 
 Wi =σi-2  (6) 
The weighted standard error (σ(Aw)) is  
 σ(Aw)= ( iW )-1/2  (7) 
Table 2 displays the re-estimated Teff for the whole-body and each organ from the five 
Taiwanese female patients using the gradient of the linear regression of normalized residual 
activity.  
2.6 Internal dosimetric calculations  
While internal dosimetric calculations as a result of radioiodine therapy depend on the 
biodistribution of 131I in the whole-body, thyroid remnant and each organ, biodistribution is 
characterized by the rate of uptake and clearance. TACs were generated in the anterior 
positions of the brain, kidneys, liver, LLI, thigh, thyroid remnant, the whole-body and in the 
posterior position of the kidney (Chen et al., 2003). The Medical Internal Radiation Dose 
(MIRD) committee of the Society of Nuclear Medicine used the MIRDOSE 3 software to 
determine the radiation dose of each target organ (Sajjad et al., 2002; Stabin et al., 1999; 
Stabin, 1996; Loevinger et al., 1988; Cristy and Eckerman, 1987). The reference phantom 
selected from MIRDOSE 3 was a 57 kg adult female phantom. The residence time (τh) of the 
whole-body and source organs were fitted by mono-exponential curves based on the pixels 
of an image captured by Simens E-CAM Ǆ-camera at CSMUH (Stabin, 1996).  
The area under the curve of each TAC was measured in two ways.  
1. Trapezoidal rule (Parsey et al., 2005): 
 eff i
n t
h i ii n
1
f(t )dt f(t )e dt
2
      (8) 
where f(ti) = ID/100 and is the cumulative activity (Ai) for any source organ divided by the 
total activity A0 administered to the patient at time t (Stabin et al., 1999). 
2. The remaining area under the TAC to infinity was determined by the exponential drop 
in the remaining activity.  
The effective dose equivalent (EDE), measured in mGy, in any target organ is,  
 
i i i i ikA n E fEDE
m
   (9) 
where ni is the number of decays with energy Ei emitted per nuclear transition of 131I; Ei, the 
energy per disintegration (MeV); fi, the fraction of the radiation energy absorbed by the 
target; m, the mass of the target organ (kg); k, the constant of proportionality (Gy kg/MBq s 
MeV). 
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Source organ Residence Times (h)a   
 minimum Maximum AVG S D 
Bladder 0 .26 2 .30 1 .02 0 .54 
Brain 0 .43 4 .29 1 .34 1 .18 
Kidneys 0 .92 4 .43 1 .70 1 .09 
Liver 1 .53 4 .11 2 .16 1 .14 
LLI 2 .83 5 .74 3 .88 1 .15 
Remainder 8 .70 361  87 .6 109  
Thy(net) 0 .16 24 .7 6 .58 7 .30 
WB 5 .67 44 .6 28 .8 16 .0 
aAVG stands for average; bSD, standard deviation.  
Table 2. The average half-life (h) of 131I in each source organ.  
3. Results and discussion 
Figure 1 displays radioactivity distribution in the ROIs of a 46-year-old female patient (case 
no 4) in (a) 3 hours (b) 46 hours and (c) 142 hours after 131I administration. That most of the 
activity was distributed to the LLI and the thyroid on day 1 indicates the typical distribution 
of 131I. The blood activity outside by ROIs was not measured. Instead, the activity was 
determined by subtracting the activity sum of all organs from the whole-body activity. 
Medical professionals entered the activity into MIRDOSE 3 as the “remainder of the body” 
and learned that the brain takes up the least. Furthermore, Table 2 displays the maximum, 
minimum and the Teff of all five Taiwanese patients. Moreover, Table 3 and Figure 2 display 
the in vivo mean τh of the thyroidectomy patients obtained by the Ǆ-camera in various 
intervals after the 131I administration.  
 
Source organ Residence Times (h)a   
 minimum Maximum AVG S D 
Bladder 0 .26 2 .30 1 .02 0 .54 
Brain 0 .43 4 .29 1 .34 1 .18 
Kidneys 0 .92 4 .43 1 .70 1 .09 
Liver 1 .53 4 .11 2 .16 1 .14 
LLI 2 .83 5 .74 3 .88 1 .15 
Remainder 8 .70 361  87 .6 109  
Thy(net) 0 .16 24 .7 6 .58 7 .30 
WB 5 .67 44 .6 28 .8 16 .0 
aUptake values are not corrected for physical decay. The results are from a fitted line of five female 
patients. 
Table 3. The calculated 131I residence times (h) using whole-body planar images. 
3.1 Biodistributions and dosimetry 
Because the information on the Teff of 131I in the thyroid, as well as other organs, of total or 
near-total thyroidectomy patients is limited, this study estimates the radiation dose 
absorbed as a result of 131I administration. The biodistribution pattern of 131I was computed 
from 14 sequential WBSs of the five female patients. Having fitted the ratio of the activities 
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in individual organs (Ai) after the exponential decay to the first whole-body (A0) decay in 
Equation 2, medical professionals determined the Teff values of these organs. The regional 
concentrations of 131I changed significantly from hour 1 to hour 4. Figure 1 shows that a 
moderate level of background activity remained evident for 32 hours of observation. 
Furthermore, Figure 2 shows that the areas known to contain high concentrations of 131I, 
such as LLI and the liver, exhibited increasing activity. The amount of diagnostic 131I 
retained by patient no 4 dropped to 1.54% of the initial administered dose after 7 hours, and 
it did not rise after this initial decline. Whole-body images in Figure 2 demonstrate 
persistently high LLI and liver uptake as well as lower brain, kidney and bladder uptake. 
Figure 2 also displays the TACs for the whole-body, the bladder, the brain, LLI, the liver 
and the kidney; it shows that the rate of LLI activity appears to be particularly clean and 
slow. The biodistribution in the gallbladder, the colon and the esophagus could not be 
analyzed primarily because the number of pixels and counting statistics were too small. The 
thyroid remnant uptake in Patient No. 4 declined from 3.69% to 1.54% on day 1, whereas the 
uptake in the other organs began to fall rapidly at day 2. Table 4 displays the internal  
 
Source organ Internal dosimetry (mGy/MBq)   
 Minimum Maximum AVG S D  
Adrenal 0 .040 1 .34 0 .35 0 .40 
Brain 0 .039 0 .71 0 .21 0 .20 
Breasts 0 .027 1 .09 0 .27 0 .33 
Gallbladder Wall 0 .040 1 .32 0 .34 0 .39 
LLI Walla 0 .96 2 .94 2 .00 0 .67 
Small Intestine 0 .051 1 .35 0 .36 0 .40 
Stomach 0 .038 1 .34 0 .34 0 .40 
ULI Wallb 0 .042 1 .40 0 .36 0 .40 
Heart Wall 0 .034 1 .34 0 .33 0 .40 
Kidneys 0 .22 2 .04 0 .89 0 .46 
Liver 0 .064 0 .79 0 .32 0 .20 
Lungs 0 .032 1 .25 0 .31 0 .38 
Muscle 0 .033 1 .21 0 .29 0 .36 
Ovaries 0 .07 1 .46 0 .41 0 .42 
Pancreas 0 .04 1 .39 0 .35 0 .41 
Red Marrow 0 .038 1 .29 0 .32 0 .38 
Bone Surfaces 0 .037 1 .38 0 .34 0 .41 
Skin 0 .026 1 .03 0 .25 0 .31 
Spleen 0 .037 1 .32 0 .34 0 .39 
Thymus 0 .032 1 .28 0 .31 0 .39 
Thyroid 0 .029 1 .19 0 .29 0 .38 
Urine Bladder Wall 0 .042 1 .29 0 .31 0 .42 
Uterus 0 .048 1 .42 0 .36 0 .42 
Total body 0 .038 1 .20 0 .31 0 .36 
Eff Dose Equiv.c 0 .11 1 .42 0 .49 0 .37 
Eff Dosec 0 .16 1 .49 0 .55 0 .38 
aLLI stands for lower large intestine; bULI, upper large intestine.  
cThe units for effective dose and effective dose equivalent are mGy/MBq. 
Table 4. The estimated amount of radiation dose absorbed (mGy/MBq) as a result of 131I 
administration. 
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dosimetric evaluations (mGy/MBq) evaluated from each patient’s TACs using MIRDOSE 3 
and states the radiation dose absorbed by each organ. The three organs with the highest 
exposures were the LLI wall, the kidneys and the ovaries. 
3.2 Teff of whole-body and other organs 
According to Equation 1, Teff was determined by the biological elimination and physical 
decay of 131I activity (Chen et al., 2003; Stabin et al., 1999; Berg et al., 1996; Stabin 1996; 
Synder et al., 1983). An important step in generating the TACs and determining the dose 
required for thyroidectomy patients is to calculate the exact Teff of each organ of interest. 
Dunning and Schwarz (1981) determined that large uncertainties might be primarily 
associated with the patient’s age, and the physiological and metabolic characteristics of each 
organ. 
Using planar images to analyze data yields conservative estimates of activities because the 
large ROIs include overlying tissues, as displayed in Figure 1. The Teff of 131I for Graves’ 
disease is 5.0±0.16 days (s.d. = 1.3); toxic nodular goiter, 6.0±0.12 days (s.d = 1.2) as reported 
by Berg et al. (1996). Figure 2 shows that 131I-NaI was clearing from the whole-body at an Teff 
of 22.7±16.3 hour, which is consistent with that obtained by Pacilio et al. (2005), who also 
found that the median and mean (±1 standard deviation) Tbio distribution of 225 ablation 
treatments were 0.63 days and 0.70±2.25 days, respectively. In this study, the whole-body 
Teff values of five female patients who have undergone a total or near-total thyroidectomy 
ranged from 15.4 to 175.4 hours and Tbio was 31.9±4.8 hours. These data correlated well with 
2.18±1.45 days of complete ablation patients, reported by Samuel and Rajashekharrao (1994) 
as displayed in Table 5. Samuel and Rajashekharrao (1994) also reported ranges of 0.83 to 
3.7 day for complete ablation patients and 1.6 to 5.0 days for partial ablation patients; these 
numbers are also displayed in Table 5. Furthermore, Samuel and Rajashekharrao (1994) 
employed a portable ǃ-Ǆ exposure rate meter to measure the 131I activity in residual thyroid 
tissue in the neck region directly in order to evaluate the Teff of 131I. Using Ǆ-camera in vivo at 
CSMUH may yield more precise results than using a portable ǃ-Ǆ exposure rate meter. 
North et al. (2001) obtained an Teff of 0.71 days in complete ablation patients who received 
1.7-13 GBq of 131I, which is greater than the 1100 MBq dose in this study. Furthermore, this 
study included only five patients, and therefore the results should be considered as 
preliminary estimates only. Although the patients were all female, the biodistribution is not 
expected to differ significantly due to gender. 
3.3 Internal medical dosimetry 
The MIRDOSE 3 software can be used to determine the effective dose as defined by ICRP 23. 
Internal medical dosimetry was conducted for each subject independently, and the results 
were averaged. Table 4 displays the average dose amount absorbed by the six principal 
target organs in the five female patients. LLI absorbed the most radiation (2.00±0.67 
mGy/MBq), ranging from 0.96 to 2.94 mGy/MBq; the kidney (0.89±0.46 mGy/MBq), 
second; the ovaries (0.41±0.42 mGy/MBq), third. The species as well as physiological and 
metabolic characteristics may account for the differences. These τh obtained from the fitted 
lines of individual organs were highest in the LLI wall (3.88±1.15 hours) and then in the 
liver (2.16±1.14 hours), as displayed in Table 3. Self-dose, according to MIRDOSE 3, was the 
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main contributor to the dose absorbed by all of the organs listed in Table 4. The effective 
dose was 0.55±0.38 mGy/MBq and effective dose equivalent was 0.49±0.37 mGy/MBq, 
which did not include the effective dose of the thyroid remnant, and was lower the 16.00 
mSv/MBq reported by Weng et al. (1989), who determined the values by either EDE per 
radiopharmaceutical drug or an published procedure of data in Kaohsiung from 1977 to 
1988.  
 
Pathology Therapeutic dose 
(131I) 
Effective Half-Life 
(day) 
Method Reference 
Thyroidectomy 1.1 GBq 22.7±16.3 (hr) E-CAM 
Ǆ-camera 
This work 
Extrathyroidal 1.22 GBq 0.32 Model USNRC, 1997 
Complete 
ablation 
3.4 ± 2.4 GBq 2.18 ± 1.45 Exposure rate 
meter 
Samuel, and 
Rajashekharrao, 
1994  
Thyroid cancer 3.7-7.4 GBq 2.2± 0.8 Ǆ-camera Mathieu, 1996 
Total lobectomy 1.1 GBq 5 Rectilinear 
scanner 
Synde, 1983 
Grave’s disease 0.5 MBq 5.0± 1.56 2-inch NaI 
neck uptake 
Berg, 1996 
Toxic nodular 
goiter 
0.5 MBq 6.0± 1.2 2-inch NaI 
neck uptake 
Berg, 1996 
Normal, Adults Trace amount Tbio =120 
Tbio =12 
Model ICRP 30 
Table 5. The effective half-life of 131I for whole-body therapy. 
Beekhuis et al. (1988) found large variations among medical internal doses across hospitals 
that apply various radioactivity dose levels in similar investigations (Beekhuis et al., 1988). 
Furthermore, Beekhuis et al. (1988) established that EDEs were rough estimates of real 
radiation burdens. The dose required for ablation is directly related to the mass of the 
remnant, thus using US, CT or MRI to evaluate organ and tumor mass yields more accurate 
and reproducible results (Rosario et al., 2004). Published reports by Comtois et al. (1993) also 
strongly asserted that 1100 MBq of 131I, the dose applied in this study, can ablate residual 
thyroid tissues completely. Moreover, the 1100 MBq dose reduces the financial burden on 
the patients who no longer require hospitalization (CSMUH, 2005).  
4. Conclusion 
To our knowledge, this study is the first attempt to re-calculate biodistributions, Teff and the 
internal medical dosimetric data for Taiwanese female 131I patients. The Teff for the thyroid 
was 22.7±16.3 hours and for the whole-body was 69.5±70.9 hours. Table 5 shows that the 
results differ significantly from those reported by ICRP 30, but are consistent with Samuel 
and Rajashekharrao’s (1994) 2.18±1.45 days for patients who exhibited complete ablation. 
Despite the consideration of thyroid remnant, the medical internal doses in this study were 
highest in LLI, 2.00±0.67 mGY/MBq, and second highest in the kidney, 0.89±0.46 mGy/MBq 
as determined by using the trapezoidal rule to evaluate the area under the TACs. Based on 
an effective dose of 0.55±0.38 mGy/MBq for the five thyroidectomy patients at CSMUH, the 
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biodistributions and Teff can be easily estimated from medical images obtained using 
Siemens E-CAM coincidence Ǆ-camera. 1100 MBq of 131I could be safe and sufficient to 
administer to total thyroidectomy patients. 
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